Polatuzumab Vedotin

Definition

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. Upon administration, the monoclonal antibody moiety of polatuzumab vedotin selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.

Also known as ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, FCU-2711, FCU2711, POLATUZUMAB VEDOTIN, polatuzumab vedotin-piiq, Polivy, RG 7596, RG-7596, RG7596, Ro 5541077-000 — per NCIT

Also identified as

• ATC L01FX14 per RXNORM
• NCIT NCIT:C104153 per NCIT
• SCTID 788328006 per RXNORM
• SCTID 788329003 per RXNORM
• UNII KG6VO684Z6 per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.